News & Events about Werewolf Therapeutics Inc.
Werewolf Therapeutics, Inc. (NASDAQ:HOWL Get Rating) Director Ra Capital Management, L.P. purchased 1,853,000 shares of the firms stock in a transaction on Friday, January 6th. The shares were purchased at an average cost of $2.21 per share, with a total value of $4,095,130.00. ...
Thinking about buying stock in Biora Therapeutics, AMC Entertainment, Werewolf Therapeutics, Broadwind, or BioNano Genomics? Thinking about buying stock in Biora Therapeutics, AMC Entertainment, Werewolf Therapeutics, Broadwind, or BioNano Genomics? PR Newswire NEW YORK, Jan. 11, 2023 NEW YORK...
Globe Newswire
2 months ago
- mWTX-330 is designed as a systemically delivered, conditionally activated IL-12 therapy and is a member of a novel class of INDUKINE therapeutics - - Preclinical data supports the development of WTX-330, Werewolfs product candidate, for the potential treatment of selected advanced or metastatic ...
Globe Newswire
9 months ago
WTX-124 demonstrated high tumor selectivity and generated significant anti-tumor activity in a CD8+ T cell-dependent manner WTX-330 surrogate demonstrated significant expansion of the therapeutic window, compared to recombinant IL-12, and generated potent anti-tumor immunity in multiple syngeneic ...
On Thursday, 112 stocks made new 52-week lows.
read more...